Detalhe da pesquisa
1.
Biomarker subset analysis of a phase IIIb, open-label study of afatinib in EGFR tyrosine kinase inhibitor-naive patients with EGFRm+ non-small-cell lung cancer.
Future Oncol
; 18(12): 1485-1497, 2022 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-35114807
2.
Therapeutic Potential of Afatinib in NRG1 Fusion-Driven Solid Tumors: A Case Series.
Oncologist
; 26(1): 7-16, 2021 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32852072
3.
Afatinib and radiotherapy, with or without temozolomide, in patients with newly diagnosed glioblastoma: results of a phase I trial.
J Neurooncol
; 155(3): 307-317, 2021 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-34787778
4.
Experience from Asian centers in a named-patient-use program for afatinib in patients with advanced non-small-cell lung cancer who had progressed following prior therapies, including patients with uncommon EGFR mutations.
Int J Clin Oncol
; 26(5): 841-850, 2021 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-33783657
5.
Global named patient use program of afatinib in advanced non-small-cell lung carcinoma patients who progressed following prior therapies.
Future Oncol
; 14(15): 1477-1486, 2018 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-29376400
6.
Genomic Analysis of Tumors from Patients with Glioblastoma with Long-Term Response to Afatinib.
Onco Targets Ther
; 15: 367-380, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35422631
7.
A Phase IIIb Open-Label, Single-Arm Study of Afatinib in EGFR TKI-Naïve Patients with EGFRm+ NSCLC: Final Analysis, with a Focus on Patients Enrolled at Sites in China.
Target Oncol
; 17(1): 1-13, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35020119
8.
Second-line Afatinib or Chemotherapy Following Immunochemotherapy for the Treatment of Metastatic, Squamous Cell Carcinoma of the Lung: Real-world Effectiveness and Safety From a Multisite Retrospective Chart Review in the USA.
Clin Lung Cancer
; 22(4): 292-300.e1, 2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-33745863
9.
Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung: Final analysis of the randomised phase 3 LUX-Lung 8 trial.
EClinicalMedicine
; 37: 100940, 2021 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-34195574
10.
Afatinib in EGFR TKI-naïve patients with locally advanced or metastatic EGFR mutation-positive non-small cell lung cancer: Interim analysis of a Phase 3b study.
Lung Cancer
; 152: 127-134, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33387727
11.
Afatinib in EGFR TKI-Naïve Patients with Locally Advanced or Metastatic EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Pooled Analysis of Three Phase IIIb Studies.
Front Oncol
; 11: 709877, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-34307179
12.
Case Report: Afatinib Treatment in a Patient With NSCLC Harboring a Rare EGFR Exon 20 Mutation.
Front Oncol
; 10: 593852, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-33575211
13.
Liquid-Biopsy-Based Identification of EGFR T790M Mutation-Mediated Resistance to Afatinib Treatment in Patients with Advanced EGFR Mutation-Positive NSCLC, and Subsequent Response to Osimertinib.
Target Oncol
; 14(1): 75-83, 2019 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-30539501
14.
Afatinib in locally advanced/metastatic NSCLC harboring common EGFR mutations, after chemotherapy: a Phase IV study.
Lung Cancer Manag
; 8(3): LMT15, 2019 Sep 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-31807143
15.
Afatinib vs erlotinib for second-line treatment of Chinese patients with advanced squamous cell carcinoma of the lung.
Onco Targets Ther
; 11: 8565-8573, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-30573970
16.
Activity of Afatinib in Heavily Pretreated Patients With ERBB2 Mutation-Positive Advanced NSCLC: Findings From a Global Named Patient Use Program.
J Thorac Oncol
; 13(12): 1897-1905, 2018 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-30096481
17.
Association of ERBB Mutations With Clinical Outcomes of Afatinib- or Erlotinib-Treated Patients With Lung Squamous Cell Carcinoma: Secondary Analysis of the LUX-Lung 8 Randomized Clinical Trial.
JAMA Oncol
; 4(9): 1189-1197, 2018 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29902295
18.
Efficacy and Safety Results of the Afatinib Expanded Access Program.
Oncol Ther
; 5(1): 103-110, 2017.
Artigo
em Inglês
| MEDLINE | ID: mdl-28680960
19.
Afatinib, an irreversible ErbB family blocker, with protracted temozolomide in recurrent glioblastoma: a case report.
Oncotarget
; 6(32): 34030-7, 2015 Oct 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-26423602
20.
Phase II study of afatinib, an irreversible ErbB family blocker, in EGFR FISH-positive non-small-cell lung cancer.
J Thorac Oncol
; 10(4): 665-72, 2015 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-25514804